UBS upgraded GE HealthCare from Sell to Neutral and set a new price target of $73.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/13/2025 | $86.00 | Equal Weight | Barclays |
| 10/7/2025 | $83.00 | Buy → Neutral | Citigroup |
| 5/5/2025 | $73.00 | Sell → Neutral | UBS |
| 3/11/2025 | $85.00 → $100.00 | Neutral → Buy | Goldman |
| 1/8/2025 | $95.00 → $103.00 | Hold → Buy | Jefferies |
| 9/26/2024 | $84.00 → $74.00 | Neutral → Sell | UBS |
| 9/18/2024 | $100.00 | Neutral → Buy | BTIG Research |
| 9/9/2024 | $90.00 | Neutral | JP Morgan |
4 - GE HealthCare Technologies Inc. (0001932393) (Issuer)
Barclays initiated coverage of GE HealthCare with a rating of Equal Weight and set a new price target of $86.00
Citigroup downgraded GE HealthCare from Buy to Neutral and set a new price target of $83.00
UBS upgraded GE HealthCare from Sell to Neutral and set a new price target of $73.00
10-Q - GE HealthCare Technologies Inc. (0001932393) (Filer)
8-K - GE HealthCare Technologies Inc. (0001932393) (Filer)
144 - GE HealthCare Technologies Inc. (0001932393) (Subject)
GE HealthCare (NASDAQ:GEHC) is announcing that members of its management team will present at the following upcoming investor conference. Jefferies Global Healthcare Conference in London, England – Tuesday, November 18, 2025 at 9:30 am GMT/4:30 am ET/3:30 am CT A webcast of this event can be accessed at the GE HealthCare website: https://investor.gehealthcare.com/news-events/events on the date and time listed above. About GE HealthCare Technologies Inc. GE HealthCare is a trusted partner and leading global healthcare solutions provider, innovating medical technology, pharmaceutical diagnostics, and integrated, cloud-first AI-enabled solutions, services and data analytics. We aim t
Revenue growth was 6% and Organic revenue growth* was 4% year-over year, driven by Europe, the Middle East and Africa (EMEA) and the U.S. Organic orders growth was 6% with growth across all segments Net income margin was 8.7%; Adjusted earnings before interest and taxes (EBIT) margin* was 14.8% Diluted earnings per share (EPS) were $0.98; Adjusted EPS* was $1.07 Cash flow from operating activities was $593 million; Free cash flow* was $483 million Excluding tariff impacts, margin and EPS would have exceeded prior year Raises the lower end of full-year 2025 Adjusted EPS* guidance range and reaffirms all other metrics GE HealthCare (NASDAQ:GEHC) today reported fina
NetworkNewsWire Editorial Coverage NEW YORK, Oct. 21, 2025 /PRNewswire/ -- Artificial intelligence (AI) is making inroads into every corner of medical technology, perhaps none more urgently than imaging. In breast cancer detection, where early diagnosis can mean the difference between life and death, AI-enhanced modalities present a chance to leap beyond the limits of mammography, tomosynthesis, and MRI. Globally, breast cancer remains one of the most common cancers in women. According to the World Health Organization (WHO), more than 2.3 million women were diagnosed with breast cancer in 2022, and approximately 670,000 women died from the disease globally. In the United States, the American
4 - GE HealthCare Technologies Inc. (0001932393) (Issuer)
4 - GE HealthCare Technologies Inc. (0001932393) (Issuer)
4 - GE HealthCare Technologies Inc. (0001932393) (Issuer)
Revenue growth was 6% and Organic revenue growth* was 4% year-over year, driven by Europe, the Middle East and Africa (EMEA) and the U.S. Organic orders growth was 6% with growth across all segments Net income margin was 8.7%; Adjusted earnings before interest and taxes (EBIT) margin* was 14.8% Diluted earnings per share (EPS) were $0.98; Adjusted EPS* was $1.07 Cash flow from operating activities was $593 million; Free cash flow* was $483 million Excluding tariff impacts, margin and EPS would have exceeded prior year Raises the lower end of full-year 2025 Adjusted EPS* guidance range and reaffirms all other metrics GE HealthCare (NASDAQ:GEHC) today reported fina
GE HealthCare (NASDAQ:GEHC) will announce its third quarter 2025 financial results before the market opens on Wednesday, October 29, 2025. The GE HealthCare management team will also host a conference call and webcast at 8:30 a.m. Eastern Time / 7:30 a.m. Central Time on that same day, which will be a live webcast and accessible at https://investor.gehealthcare.com/news-events/events. The earnings release, accompanying financial information, and webcast replay also will be posted at the same link on the GE HealthCare Investor Relations website. About GE HealthCare Technologies Inc. GE HealthCare is a trusted partner and leading global healthcare solutions provider, innovating medical te
The Board of Directors of GE HealthCare Technologies Inc. (NASDAQ:GEHC) today declared a cash dividend of $0.035 per share of Common Stock for the third quarter of 2025 payable on November 14, 2025 to all shareholders of record as of October 24, 2025. About GE HealthCare Technologies Inc. GE HealthCare is a trusted partner and leading global healthcare solutions provider, innovating medical technology, pharmaceutical diagnostics, and integrated, cloud-first AI-enabled solutions, services and data analytics. We aim to make hospitals and health systems more efficient, clinicians more effective, therapies more precise, and patients healthier and happier. Serving patients and providers for
SC 13G/A - GE HealthCare Technologies Inc. (0001932393) (Subject)
SC 13G/A - GE HealthCare Technologies Inc. (0001932393) (Subject)
SC 13G/A - GE HealthCare Technologies Inc. (0001932393) (Subject)
BOCA RATON, Fla., June 2, 2025 /PRNewswire/ -- PharmaLogic Holdings Corp. ("PharmaLogic" or "the Company"), a leading contract development and manufacturing organization (CDMO) specialized in radiopharmaceuticals, today announces the Company has appointed Etienne Montagut, currently serving as President, to the position of President and Chief Executive Officer, effective as of 1 June 2025. Mr. Montagut brings over 25 years of senior leadership experience in the pharmaceutical sector, with a solid track record of driving growth and executing strategic transformation across glob
GE HealthCare (NASDAQ:GEHC), a leading global healthcare solutions provider, announced the appointment of Jeannette Bankes as president and CEO, Patient Care Solutions, effective May 1, 2025. Peter Arduini, president and CEO, GE HealthCare, said, "Jeannette is a proven leader who has diverse and deep experience at publicly traded companies in the healthcare industry. We proudly welcome her to the company and are confident that she has the expertise to move Patient Care Solutions forward and deliver on our precision care strategy." Bankes brings with her three decades of global experience including product management, marketing, sales, regulatory, medical affairs, and operations and manufa
Collaboration has always been important in the healthcare industry, but in this era of digital health, teamwork across institutions has become essential Enhancing Elekta's radiation therapy offerings with GE HealthCare's MIM Software medical imaging management solutions will help drive greater benefits for global healthcare systems This new collaboration complements GE HealthCare and Elekta's existing global commercial collaboration agreement, which enables the two companies to provide hospitals and cancer patients a comprehensive radiation therapy offering across imaging and treatment Weeks after closing its acquisition of MIM Software – a global provider of medical imaging analy